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Abstract: p53, first described four decades ago, is now established as a master regulator of cellular
stress response, the “guardian of the genome”. p53 contributes to biological robustness by behaving
in a cellular-context dependent manner, influenced by several factors (e.g., cell type, active signalling
pathways, the type, extent and intensity of cellular damage, cell cycle stage, nutrient availability,
immune function). The p53 isoforms regulate gene transcription and protein expression in response
to the stimuli so that the cell response is precisely tuned to the cell signals and cell context. Twelve
isoforms of p53 have been described in humans. In this review, we explore the interactions between
p53 isoforms and other proteins contributing to their established cellular functions, which can be both
tumour-suppressive and oncogenic in nature. Evidence of p53 isoform in human cancers is largely
based on RT-qPCR expression studies, usually investigating a particular type of isoform. Beyond
p53 isoform functions in cancer, it is implicated in neurodegeneration, embryological development,
progeroid phenotype, inflammatory pathology, infections and tissue regeneration, which are described
in this review.
Keywords: p53; isoforms; cancer; p53 response
1. Introduction
p53, first described four decades ago, is established as the “guardian of the genome” or master
regulator of cellular damage response [1]. In response to a mutagenic or stress stimulus (e.g., nutrient
deprivation) or changes in cell signalling and tissue homeostasis, p53 is activated, initiating different
adaptive protein expression programs to maintain/restore tissue integrity and biological functions
by triggering and coordinating different cell fate decisions in the diverse cell types composing the
damaged organs. p53 induces and coordinates cell repair, cell survival, senescence, migration of
immune, endothelial and progenitor cells, stem-cell renewal, differentiation and cell death depending
on the cell type and function, the active signalling pathways, the type of damage, the cell cycle stage,
nutrient availability, the immune response and the presence of pathogens [2–7].
p53 is at the hub of the cell signal pathways, being modified post-translationally and simultaneously
by a plethora of diverse modifying enzymes (acetyl-transferase, deacetylase, methyltransferase,
demethylase, ubiquitin-ligase, deubiquitinase, kinases, phosphatases, Poly-ADP ribose polymerase
(PARP)) that are regulated by very different cell sensors and receptors [2,3,8]. In other words, p53,
via regulating gene expression, integrates simultaneously many different cell signals and contribute to
their translation into a cellular response precisely adapted to the type and context of the cell.
Adopting a dualistic perspective, the seemingly paradoxical effects of p53 become apparent,
for instance, being able to transactivate both proapoptotic (BAX, PUMA and NOXA) and anti-apoptotic
(p21, 14-3-3σ) genes. Aptly described as “antagonistic bifunctionality”, this highlights the nature of p53
to mediate varied, at instances paradoxical cellular responses, influenced by the dynamic environment
the cell is in [9,10]. Further supporting its dualistic nature, the cellular biochemical functions of p53,
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in addition to expected tumour suppressive effects, can have an oncogenic influence. The extent of the
p53-mediated cellular functions still remains undefined. Furthermore, unlike conventional tumour
suppressors, which are not expressed in human cancers due to non-sense mutation (stop) or gene
deletion, p53 often undergoes missense mutations that do not entirely abolish all p53 biochemical
activities [11,12]. It may explain why TP53 mutations despite being the most frequently observed in
human cancers, do not strictly correlate at the individual level to the patient’s clinical outcome [13–15].
The two distinct promoters of TP53 gene (P1: upstream of exon1, and P2: within intron4),
the alternative splicing and the alternative translation initiation sites of the different TP53 mRNA
lead to the co-expression of p53 proteins with different protein-interacting domains and activities
(p53 isoforms) [16,17]. This review focuses on the current understanding of p53 isoforms and explores
their established implications in both physiology and disease.
2. Generation of Human p53 Isoforms
The human TP53 gene, as a transcription factor, comprises 13 exons (11 exons and 2 alternate
spliced exons) located on chromosome 17p13.1 [18]. First observation of p53 splice variants was
reported in the mid-1980s, but it was only 25 years after that TP53 splice variants were discovered in
various species, and their biological and clinical relevance established [19,20]. Alternative splicing of
human TP53 intron 9 was subsequently described. Till date, twelve protein isoforms of p53 (p53α, p53β,
p53γ, ∆40p53α, ∆40p53β, ∆40p53γ, ∆133p53α, ∆133p53β, ∆133p53γ, ∆160p53α, ∆160p53β, ∆160p53γ)
encoded by 9 TP53 mRNA transcripts, expressed differentially in tissues, have been described and
characterized in humans [16,21–24].
p53 isoforms are generated as a result of a combination of the use of alternative promoters (P1 and
P2), alternative splicing and alternative initiation of translation [22]. Canonical TP53 transcription
initiates at promoter P1. In humans, alternative splicing can occur to produce variants retaining intron
2 and intron9. Alternative splicing at intron 9 can produce mRNA variants with either inclusion of
exon 9β or 9γ, giving rise to β and γ isoforms, respectively. Stop codons are present in exon 9β and
9γ; hence exons 10 and 11 remain untranslated for the β and γ TP53 mRNA splice variants. The p53
mRNA transcribed from P1 promoter with spliced-out intron-2 can be translated from the first AUG
(present in exon 2) generating p53α, p53β and p53γ proteins and from AUG40 due to an internal
ribosome entry site in the 5′UTR from exon1-exon2 leading to the co-expression of ∆40p53α, ∆40p53β,
∆40p53γ isoforms [25,26]. From the TP53 mRNA transcripts retaining the intron 2 (which contains
stop codons), translation can only be initiated at AUG 40 producing thus only the ∆40p53 isoforms
(∆40p53α, ∆40p53β, ∆40p53γ isoforms) [16,22].
Transcription of TP53 mRNA can initiate from internal promoter P2 located at intron 4. Translation
of these transcripts from initiating codons 133 and 160 can generate ∆133p53 and ∆160p53 isoforms,
respectively. Considering alternative splicing at intron 9, these transcripts give rise to isoforms
(∆133p53α, ∆133p53β, ∆133p53γ, ∆160p53α, ∆160p53β and ∆160p53γ isoforms) [22].
3. Conservation and Structure of p53 and Its Isoforms
The TP53 gene has a dual gene structure that is conserved in several species such as zebrafish,
drosophila, mouse and humans [22,27]. In drosophila, the Dmp53 gene is the biological functional
equivalent of the TP53 gene. Two protein isoforms, DTAp53 and D∆Np53, homologous to ∆40p53
isoforms have been identified to be encoded by Dmp53. DTAp53 possesses the transactivation domain
(TAD) defined by the highly conserved first 40 amino acids also detected in human p53α [16,28].
The zebrafish Zp53 gene encodes Zp53α, Zp53β, Z∆Np53α and Z∆113p5α isoforms. Other isoforms,
associated with Zp53 polymorphisms, have been detected in some zebrafish strains [28–30]. In mouse,
the TP53 homologue, MsTP53 has till date been described to encode four isoforms, Mp53α, Mp53AS,
M∆41p53α and Mp53Ψ [31,32].
p53α (canonical p53) is a DNA-sequence specific regulator of transcription orchestrating the
expression of more than 3000 genes [33]. In its active state, p53α exists as a tetramer or stacking of
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tetramer on DNA [34]. p53α contains seven functional domains, as illustrated in Figure 1. The intrinsic
disorder region (IDR), present in the N-terminal region, is an increasingly observed feature in proteins
with influential roles within a signalling cascade [35]. IDRs allow a protein to form highly specific
interactions with other functional proteins, albeit with low affinity [35,36]. The TADs comprised
within the IDR is characterized by fleeting interactions with a wide range of proteins essential to
the transcriptional activator function of p53 proteins. TADs can interact with components of the
transcription machinery, chromatin modifiers, DNA metabolism proteins (e.g., PC4, HMGB1) and
p53-modifying enzymes (e.g., MDM2, p300) [37]. From a functional perspective, TAD1 is integral for
apoptosis and DNA damage-induced G1 arrest and both TAD 1/2 for mediating specific signalling
pathways in the tumour suppressive response of p53 [38].
Figure 1. (a) p53 mRNAs. The TP53 gene encodes 9 mRNA transcripts. (b) Functional domains of
p53 and its isoforms. p53 contains seven functional domains which are the transactivation domain 1
(TAD1), the transactivation domain 2 (TAD2), the proline-rich domain (PRD), the DNA binding domain
(DBD), the hinge domain (HD), the oligomerization domain (OD) and the negative regulation domain
(α). At its N-terminus, lies an intrinsic disorder region (IDR) consisting of two acidic trans-activation
domains (TAD), TAD1 (residues 1−39) and TAD2 (residues 40–61) and a proline-rich domain (PRD)
(residues 62–93). This is followed by a DNA-binding domain (DBD) (residues 94–290) and a hinge
domain (HD) (residues 291–324). At its carboxyl terminus, p53 comprises an oligomerization domain
(OD) (residues 325–356) and a negative regulation domain (α) (residues 357–393).
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The proline-rich domain (PRD) joins TAD2 to the DNA-binding domain (DBD). It contains five
PxxP motifs generating SH3 domain binding sites. Proline-rich regions can alter the 3D-structure of
a protein though proline isomerisation (PIN1, cyclophilins) in the process regulating the orientation
and angles of the interaction of its functional domains [39]. The length of the PRD and prevalence
of specific docking sites within suggest an underlying function as a spacer or a scaffolding module
necessary for the tumour suppressive role of p53 [39–41].
The DBD is the core domain of p53 that directly interact with DNA. It comprises of an
immunoglobulin-like β-sandwich which provides the surface scaffolding for DNA binding [42].
The protein sequence of the p53 DBD contains numerous highly conserved histidine and cysteine whose
coordination with Zn2+ or Mg2+, is integral for p53 conformation and DNA-binding activity [43,44].
p53 DBD interactions with its N-terminus can contribute to the stability of the p53 tetramer [45].
Mutations in DBD can cause conformational changes and/or alterations in specificity to p53-target
DNA sequences. The propensity for carcinogenic mutations residing within this domain underscores
its importance in the tumour suppressive and homeostatic functions of p53 [46]. ∆40p53 isoforms
retain the complete DBD. In contrast, ∆133p53 isoforms lack a portion of first conserved cysteine box
of the DBD, and ∆160p53 isoforms lack the entire first conserved cysteine box of the DBD. Despite
truncations in the DBD, according to a recent publication, ∆133p53 and ∆160p53 isoforms can still
have a stable 3D conformation [47].
The hinge domain (HD) is a short linker sequence of amino-acids between the DBD and the
oligomerisation domain (OD). The HD offers structural flexibility for p53, allowing the binding of p53
response elements [48]. Germline mutations within the HD (R306P) have been associated with the loss
of p53-mediated transcriptional activation of genes such as BAX [49]. Studies involving p53 devoid of
the HD showed an inability to recognize consensus sequence, suggesting a possible role for the HD in
the allosteric regulation of DNA binding [50].
The oligomerisation domain (aa 325–356), as its nomenclature suggests, is integral for the
formation of p53 tetramers. The tetramerization process of p53 is best described as the formation
of dimers between two primary dimers. The peptide presents within the oligomerisation domain
links with another p53 monomer to form a primary dimer. This then assembles with another dimer to
form a tetrameric structure that is stabilized by hydrophobic interactions between oligomerisation
domains. Recently, lysine residues located within the oligomerisation domain, unessential for p53′s
tetramerization capability, have been identified to selectively modulate p53-mediated apoptosis and
cell-cycle arrest [51,52].
The extreme C-terminus of p53 containing the α domain is, like the TADs, an IDR. The extreme
C-terminus domain, rich in positively charged amino acids (e.g., arginine, histidine, lysine) interacts
non-specifically with negatively charged nucleic acids (RNA and DNA) [53]. Numerous proteins bind
to the C-terminus domain, explaining why missense mutated p53 protein can still be biochemically
and biologically active. The proximity of the C-terminus domain to the DNA-binding surfaces located
within the DBD offers structural support for interactions with DNA. Additionally, the disordered
α domain can form non-specific DNA interactions to allow the linear diffusion of p53α along
DNA or to transfer its movement to another DNA molecule [54]. Most importantly, the α domain
like the TAD undergoes a high degree of post-translational modifications (PTMs) which regulate
protein degradation, tetramerisation, promoter selectivity and protein-interaction with the RNA-pol II
transcriptional machinery [55].
4. p53 Isoforms Function in Concert
Various methodologies involving overexpression and/or siRNA knockdown in cell lines,
or genetically modified animal models of p53 isoform expression have been developed and used
to characterize the function of p53 isoforms [22,27]. The discovered biological functions of p53
isoforms include cell-cycle regulation, cell death, cellular senescence, inflammation, cellular invasion,
antioxidant response, tissue regeneration and stem cell renewal and differentiation, which are outlined
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in Table 1. These cellular functions of p53 isoforms have been reported in the context of both malignant
(including WT and mutant TP53) and non-malignant cells, originating from different tissues (e.g., skin,
prostate, colon).
Table 1. p53 isoforms collectively classified according to reported biomolecular functions. Respective
cell/animal models used to investigate isoform function is presented in association with observed
alteration in protein/gene expression/activity following p53 isoform manipulation. Implicated genes
are in italics.
Cellular Function
Involving p53 Isoforms Cell Line/Model(s) Studied Altered Expression or Activity Reference
Cell cycle regulation
MRC-5, WI-38 miR-34a,CDKN1A, PAI-1, IGFBP7,MMP3, BUB1, CDC20 [56]
CD8+ T lymphocytes CD62L, PD-1, LAG-3, IL-6, IL-8,SRSF3, CD28, CD57 [57]
HGPS fibroblasts STUB1, CDKN1A, IL-6, IL-8, SRSF3 [58]
Transgenic mice model IGF-1R, IGF-1, Gadd45, PTEN,MDM2, CDKN1A, IGFBP-3 [59]
Transgenic mice model p66Shc, G2-M genes [60]
Transgenic mice model MDM2, CDKN1A [61]
HASMCs EGR1, SRSF1, KLF5, p21 [62]
Human neonatal foreskin and
normal prostate tissue CDKN1A, PUMA, NOXA, hTERT [63]
129/SvJ ESCs CDKN1A, MDM2 [64]
Apoptosis
MCF7 SRSF1, p21, BAX [65]
H1299 BAX, p21WAF1 [24]
A375 melanoma cells CDKN1A, PIDD [66]
Zebrafish model CDKN1A, MDM2, BCL2L [67]
Zebrafish model CDKN1A, BAX, MDM2, BCL2L [68]
H1299 BAX [16]
HCT116, SW480, LoVo, SW620,
Colo205 RhoB [69]
Transgenic mice model ANXA5, TPT1 [70]
Transgenic mice model BIRC5, TRAF1 [61]
Human neonatal foreskin and
normal prostate tissue BAX [63]
DNA repair
HGPS fibroblasts RAD51 [58]
QSG-7701, Zebrafish model RAD51, LIG4, RAD52 [71]
Transgenic mice model VCP [70]
Saos2, HCT116, H1299 p73, RAD51, LIG4, RAD52 [72]
Inflammatory response
Transgenic mice model, SaOS2 STAT1, STAT2, OAS1g, IFI47, IFIT2,CXCL10 [73]
Transgenic mice model Alpha-enolase, TNF-alpha, CCT5,14-3-3, ALDH2 [70]
Transgenic mice model IL-6, IFN-g, TNF-alpha, IL-3, IL5,STAT1, JUNB [61]
Autophagy HCT116, H1299 p-PKR, p-elF2α, DRAM [74]
Pluripotency MCF7 SOX2, OCT3/4, NANOG [75]
129/SvJ ESCs OCT4, GATA-4, NANOG, IGF-1R [64]
Cellular invasion
MDA-MB-231, D3H2LN, MCF7,
LoVo, SW480, SW620, Colo205,
HCT116
E-cadherin, β1-integrin [76]
Transgenic mice model ITGB7, VCAM1 [61]
Transgenic mice model, HCT116 RhoA, IL-6 [77]
The biological functions of p53 isoforms are influenced by the expression of other isoforms.
The retroviral expression of p53β in human fibroblasts inhibited cell proliferation and promoted
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cellular senescence via the upregulation of p21WAF1 and miR-34. However, this effect was not observed
in TP53-null MDAH041 fibroblasts with hemizygous 1bp deletion at codon 184 (GAT-GAA, ter 244) [78],
indicating that p53β does not induce senescence on its own but through cooperation with other isoforms
produced by the TP53 gene. Similarly, ∆133p53α isoforms’ pro-proliferative activity in WT TP53
fibroblasts was not observed in TP53-null MDAH041 fibroblasts [16,56,57,65]. If some actions of
p53 isoforms are only observed in the presence of other isoforms, it is of merit to investigate their
biophysical interactions mediating cooperative behaviour.
The interactions between p53 isoforms can be direct (e.g., formation of homo-oligomers or
hetero-oligomers) or indirect (e.g., promoter-dependent oligomerisation) to convey and translate cell
signalling in a defined cell response (Figure 2).
Figure 2. Schematic overview of p53 isoform interactions mediating transactivation. (a) p53 isoforms
can form hetero-oligomers with p53α to mediate transactivation. For example, ∆40p53 α/p53α
hetero-oligomers can modulate the transcriptional activity of promoters of IGF1-receptor and Nanog,
thus controlling the switch from pluripotency to differentiation [64]. (b) p53 isoforms can transactivate
target genes only in the presence of p53α. For example, p53β can indirectly interact with p53α in the
presence of the BAX promoter DNA, modulating its promoter activity. Endogenous p53β binds to
the BAX promoter in MCF7 cells; however, the exact p53β binding sequence on the BAX promoter
remains to be elucidated [16]. (c) p53 isoforms can independently mediate transactivation. ∆40p53α can
transactivate BAX and GADD45 in p53-null cells; however, whether ∆40p53α mediates transactivation
as an oligomeric complex remains unclear (represented by dotted lines) [24]. (d) p53 isoforms can
mediate transactivation via cooperation with other proteins. p73 and ∆133p53α isoforms can cooperate
in a p53-null environment to mediate DNA repair [72].
Although the canonical oligomerisation domain, required for the direct interaction and formation
of hetero-oligomers with α-isoforms, is partially deleted in p53β isoforms, they can indirectly interact
with p53α in the presence of the BAX promoter DNA (co-immunoprecipitation of p53β and p53α in
presence of BAX promoter in H1299 cells co-transfected with p53α, p53β and Bax-luciferase reporter
plasmid) modulating its promoter activity [16,79]. In contrast, ∆40p53α and ∆133p53α isoforms
which retain the complete oligomerisation domain can directly interact with p53α (and probably
other α-isoforms) to form distinct permutation of hetero-oligomers, which would differentially
expose amino-acid domains to protein partners (i.e., Mdm2, MDMx) or cell protein machineries (i.e.,
transcriptional machinery, splicing machinery, microRNA machinery). ∆40p53α/p53α complexes can
mediate biological responses by modulating the transcriptional activity of promoters of IGF1-receptor
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and Nanog, thus controlling the switch from pluripotency to differentiation [24,64,80]. In A375
melanoma cells, ∆40p53α/p53α complexes had modified promoter activity at LRDD and CDKN1A
genes contributing to shifting cell-fate outcome in favour of apoptosis compared to cell-cycle arrest
(upregulation of PIDD and downregulation of p21) despite exposure to γ-irradiation, an established
trigger for p53-mediated DNA damage and cell cycle arrest [66].
Via direct hetero-oligomerisation, it has been reported that∆133p53α can exert a dominant-negative
effect on the apoptotic actions of p53α to favour p53 dependent DNA-repair and cell cycle
progression [56]. Recently, von Muhlinen et al. coimmunoprecipitated p53α with overexpressed
FLAG-tagged ∆133p53α and concomitantly observed decreased expression of p21 mRNA and miR-34a
mRNA, consistent with the dominant-negative inhibition of p53α-mediated cell senescence [58].
However, the dominant-negative effect of ∆133p53α on p53α is not universally observed and therefore,
is likely to be context and DNA-sequence dependent. In U2OS cells, the induction of ∆133p53α
inhibited p53α-dependent apoptosis and G1 arrest but not p53α-dependent G2 arrest [81]. Similarly,
instead of an exclusively dominant-negative relationship, the differential regulation (promoter and
stress-dependent) of ∆113p53α on p53 was observed in zebrafish [66]. Factors contributing to this
selective modulation of p53α’s transcriptional activity remain unclear. Furthermore, the functional
significance of hetero-oligomers comprising of two or more types of p53 isoforms including/excluding
p53α, has yet to be explored.
The effect of hetero-oligomerisation of isoforms can be dose-dependent, therefore influenced
by the relative expression levels of the different isoforms. ∆40p53α at low levels increased p53α’s
transactivation capacity, but at higher levels, inhibited p53α’s anti-proliferative effects [80]. Tetramers
consisting of p53α and ∆40p53α isoforms were a more stable complex compared to a purely p53α
complex [82]. One possible mechanism is that the ∆40p53α isoforms lack TAD1 precluding them from
MDM2 mediated degradation [21,24]. The actions of MDM2 in the regulation of basal levels of p53α is
in two ways. Firstly, MDM2 drives the translocation of p53α from the nucleus to the cytoplasm for
proteasomal degradation. Alternatively, MDM2 can induce the ubiquitination of p53α to unmask the
nuclear export signal located in the oligomerisation domain of p53α, making it more susceptible to
nuclear export and degradation [83]. The p53 isoforms themselves have varied subcellular localization
patterns possibly altering their susceptibility to MDM2 mediated degradation [16]. ∆40p53α isoforms,
in particular, have been preferentially found in the nucleus [84]. Indeed, MDM2 can distinguish
between p53 isoforms and differentially mediate their ubiquitination and degradation [85]. Hence,
it is possible that the susceptibility of p53 hetero-oligomers to regulatory proteins such as MDM2 is
dependent on the isoform composition adding a layer of permutation to the p53 response.
Some p53 isoforms can bind to p53-response elements to induce the p53 mediated response.
∆40p53α can bind and transactivate independently of p53α some genes such as MDM2, BAX and
GADD45 genes [24]. ∆133p53α isoforms can in response to γ-radiation upregulate the transcription
of DNA double-strand break repair genes including RAD51, RAD52 and LIG4 by binding to a novel
type of p53-responsive element in their promoters independently of p53α [71]. Alternatively, p53
isoforms can, by directly interacting or cooperating with other proteins, exert their p53α independent
cellular effects. ∆133p53β isoforms can interact with the anti-apoptotic protein, small GTPase RhoB,
to negatively regulate RhoB activity inhibiting apoptosis [69]. Vascular smooth muscle proliferation
has been found to be promoted by SRSF1, via the induction of ∆133p53a isoforms which in turn
complexes with EGR1 to activate KLF5-p21 signalling [62]. In p53 deficient H1299 cells, the increased
DNA double-strand break repair was associated with the overexpression of ∆133p53α isoforms and
was reduced upon knockdown of p73. The changes in the levels of the latter alone had no effect of
DNA double-strand break repair suggesting that p73 and ∆133p53α isoforms can cooperate in a p53α
-null environment to upregulate the transcription of DNA double-strand break repair genes including
RAD51, RAD52 and LIG4 [71,72].
Next, the question emerges as to which p53 mediated biological activities are p53α-dependent and
which ones are instead, influenced independently of p53α by the other isoforms. This has significant
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biological implications, as for example, a mutation upstream of codon 133, excluding promoter and
splice site mutations, will unalter ∆133p53αmediated DNA repair but may perturb other p53-mediated
functions reliant on WT upstream domains (i.e., apoptosis). Hence, it is conceivable that upon a TP53
mutational event and the consequential abrogation of p53α-response, unaffected WT p53 isoforms can
continue to exert their p53α-independent cellular effects influencing the severity of the consequential
carcinogenic process (Figure 3).
Figure 3. A TP53 mutational event can result in the generation of Mutp53α, WTp53 and Mutp53
isoform. Mutp53α can mediate tumorigenesis via the following mechanisms: loss of WTp53 activity by
dominant-negative effect (DNE) over the WTp53 allele. Alternatively, Mutp53α via gain of function
(GOF) mutations promote oncogenic effects in a cell context-dependent manner [86]. WTp53 isoforms
can contribute to tumour suppressive functions (e.g., ∆133p53α isoforms can coordinate with p73 to
mediate DNA repair) and may also possess intrinsic oncogenic functions (e.g., ∆133p53β isoforms
mediating angiogenesis). Preliminary evidence also suggests that WTp53 isoforms (∆160p53α) can
contribute to the GOF effects of Mutp53α [87]. The function of Mutp53 isoform in tumorigenesis
remains unclear (represented by dotted lines) but, could theoretically mediate both oncogenic and
tumour suppressive effects. Together this provides an overview of the possible downstream p53
isoform effects following a TP53 mutational event.
p53 isoforms were observed to exhibit paradoxical effects, such as promoting both cellular
proliferation and apoptosis, albeit in different cellular contexts. For example, p53β induces cellular
senescence in normal human fibroblasts, CD8+ T lymphocytes and MCF7 cells but promoted cellular
proliferation in the latter upon treatment with TG003 [65]. To guard cellular homeostasis, spatiotemporal
interactions between p53 isoforms (e.g., hetero-oligomerisation), can mediate a non-binary, robust
cellular response algorithm (to a physiological or external stimulus; e.g., DNA damage, virus) which
remains inadequately understood, contributing to the perceived paradox. Therefore, it would be
an oversimplification to merely classify individual p53 isoforms as either exclusively being tumour
suppressors or oncogenes [57,65].
In replicative senescent cells, the expression of p53β was increased and ∆133p53α decreased in
comparison to non-senescent cells [56]. The significance of protein isoform imbalance contributing
to pathology has been previously recognized, most notably in tauopathies. A shift in the normal
Int. J. Mol. Sci. 2019, 20, 6257 9 of 20
balance of tau isoforms (3R and 4R) in the human brain has been associated with abnormal neuronal
firing and cognitive impairment. Modulating the tau isoform imbalance with RNA reprogramming
(trans-splicing strategy) was associated with reduced accumulation of pathological tau and is therefore
regarded as a promising therapeutic strategy for neurodegenerative diseases and may possess similar
therapeutic value for pathology associated with p53 isoform imbalance [88]. Investigating therapeutics
at the protein level, Lei at al. showed evidence of p53 isoform modulation via introducing a p53
peptide (107–129) to stabilise and shift the conformation of ∆133p53β to that of WT p53 [47]. However,
whether the functional effects of ∆133p53β have been altered remain to be studied. This strategy
albeit preliminary may be of value in malignant pathology with increased expression of ∆133p53β,
associated with cancer invasiveness (discussed in the next section).
5. p53 Isoforms in Cancer
Dysregulation of p53 isoform co-expression may alter, without abolishing, the predicted p53
response, therefore driving carcinogenesis while simultaneously conferring sensitivity to a type of
cancer treatment. Several studies have attempted to investigate the expression of p53 isoforms in
both cancerous and normal tissues, largely utilizing RT-qPCR based assays. From these studies,
it is apparent that p53 isoform expression is not random (Table 2). In breast tumours, Gadea et al.
reported that ∆133p53α was co-expressed with other isoforms including ∆133p53γ and ∆133p53β [76].
In head and neck squamous cell cancer, p53β was found to be consistently overexpressed in almost
all samples investigated and ∆133p53 isoforms were overexpressed in non-small cell lung cancer
compared to adjacent normal tissue [89,90]. The non-random, isoform co-expression was also observed
in premalignant tissue, where p53βwas elevated and ∆133p53α reduced in colonic adenoma in contrast
to normal or non-adenoma tissue [56].
Table 2. Summary of p53 isoform expression and associated clinicopathologic outcomes in human
cancers. n refers to the number of patients from whom the samples analysed were obtained from each
study. Cholangiocarcinoma (CCA); glioblastoma (GBM); renal cell carcinoma (RCC); uterine squamous
cell carcinoma (USC); acute myeloid leukaemia (AML); squamous cell carcinoma of head and neck
(SCCHN); endometrial carcinoma (EC).
Cancer Isoforms Studied N Summary of Key Results References
Breast
∆133p53α,
∆133p53β/γ 147
Inverse association in expression of ∆133p53β mRNA with
p68 protein. [91]
p53β, ∆40p53a,
∆133p53β 47
∆133p53β isoform increased in invasive breast carcinomas
compared to non-invasive cases. [92]
p53β/γ, ∆40p53α,
∆133p53α 148
∆40p53 was increased in tumour breast tissue and associated
with aggressive subtype. p53β expression was associated with
poorer disease-free survival.
[93]
∆133p53α/β/γ 273 ∆133p53β reduced in HER2 positive tumours and is associatedwith poorer disease-free and overall survival [76]
p53β/γ 127
Mutant p53 breast tumour-expressing p53γ isoform had
improved disease-free survival. p53β was associated with
tumour oestrogen receptor (ER) expression
[94]
∆40p53α 139 Reduced ∆40p53α:p53 ratio associated with improveddisease-free survival. [95]
Ovarian
∆40p53α,
∆133p53α 169
No difference in p53 isoform expression between stage I and III
ovarian cancer. [96]
∆40p53α,
∆133p53α 166
∆40p53α expression associated with improved disease-free
survival in patients with mucinous ovarian cancer with WT
TP53. Increased ∆133p53 expression in endometroid
ovarian cancer.
[97]
∆40p53α,
∆133p53α 154
∆133p53 expression associated with improved disease-free and
overall survival in p53 mutant serous ovarian cancer. Increased
∆40p53 expression associated with improved disease-free
survival but not overall survival in p53 WT serous
ovarian cancer.
[98]
p53α/β/γ,
∆133p53α 69
No difference in isoform expression between chemo responders
and non-chemo responders. Increased ∆133p53α expression
significantly associated with improved overall survival and
borderline significance for improved disease-free survival.
[99]
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Table 2. Cont.
Cancer Isoforms Studied N Summary of Key Results References
Colon
p53β, ∆133p53α 29
Colon adenoma tissues expressed elevated p53β and reduced
∆133p53α expression compared with non-adenoma and normal
colon tissue. ∆133p53 isoform expression was significantly
higher in carcinoma tissue
[56]
∆133p53α/β 35 Increased ∆133p53α expression associated with poorerdisease-free survival. [77]
CCA ∆133p53α 48 Increased ∆133p53 and ∆133p53/p53a expression associatedwith a poorer overall survival. [100]
GBM
∆40p53α, p53β 17 ∆40p53α was observed in glioblastoma tissue which was notdetected in non-tumour cerebral cortex. [101]
p53β, ∆40p53α,
∆133p53α 89
∆133p53β expression increased on a wild-type TP53
background in glioblastoma. [102]
RCC
p53β/γ,
∆133p53α/β/γ 41
p53β mRNA was overexpressed in tumour samples and
correlated with tumour stage. [103]
p53β/γ 268 p53β expression was associated with improved disease-free andoverall survival in p53 mutant patients. [104]
p53α, ∆40p53α,
∆133p53α 41
Expression of p53 p53α, ∆40p53α, ∆133p53α was increased in
mutant TP53 RCC compared to WT TP53 RCC. [105]
EC p53β/γ, ∆40p53α,∆133p53α 37
Increased p53γ expression is associated with poorer
disease-free survival [106]
AML p53β/γ 68 p53β and p53γ expression correlated with mutated NPM1,a marker of improved overall survival. [107]
SCCHN p53β/γ,∆133p53α/β/γ 21 p53β/γ, ∆133p53α/β/γ were detected in tumour tissue. [89]
Lung ∆133p53α 17 Overexpression of ∆133p53 mRNA was observed in canceroustissue as compared to adjacent non-cancerous tissue. [90]
Melanoma
p53α/β/γ,
∆40p53α/β/γ,
∆133p53α/β/γ,
∆160p53α
38
In tumour tissue, ∆40p53β expression was reduced, whereas
∆133p53α and ∆160p53α expression was increased. Reduced
p53β expression or increased ∆133p53β and p53α mRNA
expression were associated with poorer overall survival.
[108]
Up to now, clinical studies have largely investigated one isoform at a time, however, it is becoming
clear that the p53 isoforms are co-expressed and work in concert to define cellular responses. Therefore,
to better understand p53 isoform activities, future studies evaluating the relationship between p53
isoform expression and clinical outcomes should adopt investigating the co-expression of the different
p53 isoforms in combinations.
The increased expression of p53β has been associated with improved disease-free survival in breast
and clear cell renal cell carcinoma [93,104]. In cancer cell lines and normal fibroblasts endogenously
co-expressing p53 isoforms, the overexpression of p53β induces apoptosis and cell senescence via
the upregulation of genes such as BAX and p21/miR34 in a p53-dependent manner [56]. The tumour
suppressive effects observed in cell studies may explain the improved cancer outcomes associated with
the expression of p53β. The expression of the alternate C-terminal variant p53γ, with other isoforms,
is predominantly associated with reduced risk of cancer progression as reported in breast and uterine
squamous cell carcinoma [94,106].
The expression of ∆40p53α is higher in tumours than normal tissue in both glioblastoma and
breast cancer [93,101]. The clinically more aggressive triple-negative breast cancer subtype is associated
with increased ∆40p53α expression [93]. Contrastingly, in mucinous ovarian cancer, the expression of
∆40p53α is associated with improved disease-free survival [97]. Taking this together, the biological
relevance of ∆40p53α is evident, however, it is not possible to attribute to it an absolute oncogenic or
tumour suppressive role since its activity is dependent on cell function, cell context and the co-expressed
driver oncogenes.
The overexpression of ∆133p53α in tumour tissue has been reported in cholangiocarcinoma, lung,
colon and ovarian cancers [56,90,98,100]. In lung cancer tissue, p21 expression was reduced whereas
∆133p53α was overexpressed, however, this inverse relationship did not reach statistical significance
possibly owing to the small sample size [90]. Further evidence of this relationship is observed in breast
cancer, where ∆133p53α inhibits the ability of p68 to induce p53-dependent transcription from the p21
promoter [91]. This suggests that tumour cells with ∆133p53α expression could have reduced ability
to undergo p21 mediated cell-cycle arrest. Increased ∆133p53α isoform expression, in the context
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of WT TP53, has been associated with poorer disease-free survival in patients with colorectal cancer.
A possible mechanism explaining this association is ∆133p53α isoform mediated tumour cell invasion
via increased IL-6 expression activating JAK-STAT3 and RhoA-ROCK pathways [77]. Interestingly,
in advanced serous ovarian cancer tissue with mutant TP53 gene, ∆133p53α expression was associated
with improved disease-free survival and overall survival, providing preliminary evidence that the
mutational status of TP53 can influence the association between p53 isoform expression and patients’
clinical outcome.
In breast cancer, ∆133p53β expression was significantly associated with an increased risk of cancer
recurrence and poorer overall survival [76,92]. In HCT116 cells, ∆133p53β expression was found
to promote the acquisition of an amoeboid-like phenotype associated with epithelial mesenchymal
transition and cell invasiveness [76]. Recently Kazantseva et al. showed that the expression of∆133p53β,
which was increased in glioblastoma tissues with WT p53, promoted an immunosuppressive tumour
microenvironment by increasing CCL2 expression and subsequent CD163 macrophage infiltration [102].
Taken together, it is becoming apparent that ∆133p53β co-expression with other p53 isoforms could be
associated with poorer cancer outcomes.
The expression and cellular effects of p53 isoforms can be influenced by the mutational status
of TP53. Therefore, it is recommended that the p53 isoform expression is reported with respect to
the mutational status of TP53, to establish more precise correlations with clinical outcomes [109,110].
However, stating whether p53 is WT or mutant may not suffice as it is becoming apparent that the
mutational landscape of p53 is highly heterogeneous and the various p53 mutants are not equal in their
cellular and phenotypical effects [111,112]. For example, Li Fraumeni syndrome (LFS) patients with
specific p53 DBD mutations (associated with impaired anti-proliferative functions in H1299 cultured
cells) have tumour incidences at an earlier age compared to LFS patients harbouring germline TP53
mutations retaining anti-proliferative functions [112].
A feasible step towards representing p53 isoform expression in relation to the heterogeneous
p53 mutations would be to adopt a functional-domain oriented approach by classifying p53 mutants
as follows: TAD, oligomerisation domain and DBD mutants [113]. Studies investigating mutations
(missense mutations, insertions and deletions) within the TAD of p53 revealed that these mutations
often introduce a stop codon upstream of the ATG codon in exon 4, disrupting the expression of p53α.
These mutants, classified as TAD mutants of p53, consequentially express all p53 isoforms except p53α,
p53β and p53γ. As these mutants still possess the ability to partially transactivate p53-dependent
genes, including pro-apoptotic genes, TAD mutants could be generally more responsive to treatment
and associated with a better prognosis than DBD mutants [113,114]. The impact of a mutation in the
exons coding for the oligomerisation domain and DBD on the expression of p53 isoforms is less clearly
defined as compared to that of TAD mutants.
Select p53 isoforms are often studied in isolation, leaving the implications of any potential
changes in other isoforms unclear. As a type of p53 isoform is never expressed exclusively as a
single p53 protein in cancer or normal cells, characterisation of their combined activities is required
to recapitulate physiological expression. Nutthasirikul et al. identified that the ∆133p53α/p53α
ratio was an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma [100].
A lower ∆40p53α:p53α ratio was associated with reduced cancer progression in breast cancer [95].
With consistent associations being observed (e.g., p53β expression correlating with a better prognosis),
a concerted effort to decipher how the combined co-expression of various isoforms and type of p53
mutation alter cancer prognosis and survival is required.
6. Implications of p53 Isoforms Beyond Cancer
The role of p53 in embryological development has been a perplexing puzzle that has not yet been
fully understood, and more than one type of p53 isoform has been implicated. p53 null mouse, zebrafish
and drosophila models have been developed showing different embryogenic abnormalities and also
possess a phenotype characterized by an increased incidence of cancers at an earlier age [115–119].
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When p53 was overexpressed or hyperactivated in transgenic animal models, embryonic defects were
observed with consequential phenotype influenced by the magnitude and spatiotemporal pattern
of p53 activation [120]. In mouse models with TP53 expressing ∆122p53, isoforms (equivalent to
human ∆133p53) were associated with abnormalities in embryogenesis, with a predilection for female
embryos. These include exencephaly, ophthalmoplegia, ectopic vertebrae and foetal reabsorption [31].
In zebrafish, the loss of function mutation in the Def gene impaired digestive organ growth and
induced the expression of the Z∆113p53α isoform [115]. This suggests that in the zebrafish Z∆113p53α
isoforms are negatively regulated by the Def gene during embryogenesis to avoid dysregulation of
organogenesis. Taken together, these indicate that the Z∆113p53α isoforms could have a role in normal
embryogenesis and whether this is p53α dependent remains unclear [30].
Transgenic mice ectopically expressing∆40p53α isoform in the presence of WT p53 had a progeroid
phenotype consistent with accelerated ageing (reduced bone mineral density and loss of fertility).
The disrupted ∆40p53α:p53α isoform ratio in these mice was associated with the upregulation of IGF-1
signalling [59]. ∆40p53α isoforms functionally inactivate PTEN which regulates IGF signal transduction
to Akt, thus dysregulating IGF-1 signalling and consequentially promoting cellular senescence and
reduced proliferation. Glucose homeostasis was also adversely affected in ∆40p53α transgenic mice,
characterized by early-onset hyperinsulinemia and glucose intolerance, resulting in hyperglycaemia
and impaired proliferation of β-cells in the pancreas. Abnormal β-cell growth homeostasis could be
a result of dysregulated Akt regulation of CDK4, cyclin D1 and cyclin D2 via the effects ∆40p53α
isoforms on IGF1 signalling [121]. In the rare progeria disease, Hutchinson–Gilford progeria syndrome
(HGPS), the premature ageing phenotype has been associated with the overexpression of p53β and
the reduction of ∆133p53α isoforms. Further analysis in proliferative HGPS fibroblasts with the
depletion of ∆133p53α isoforms was associated with increased mRNA expression of p53 target genes
associated with cellular senescence (p21/CDKN1A), senescence-associated secretory phenotype (SASP)
and pro-inflammatory cytokines (IL-6 and IL-8), hence explaining the progeria phenotype [58].
Ageing is a direct risk factor for neurodegenerative conditions such as Alzheimer’s disease.
In a mouse model, the overexpression of ∆40p53α isoform, associated with an accelerated ageing
phenotype, conferred dysregulated tau phosphorylation and cognitive dysfunction. The mouse
∆40p53α isoform was observed to promote tau phosphorylation via binding to promoters and inducing
transcription of several kinases (Dyrk1A, GSK3β, Cdk5, p35, and p39) [58]. Overexpression of p53β in
WT TP53 expressing cells, consistent with investigations from cancer cell lines, induced senescence
in astrocytes. In a state of senescence, cells secrete a host of cytokines, proteases and growth factors
that alter the tissue microenvironment [122]. However, when astrocytes are in a state of senescence,
the resulting SASP induces neurotoxicity which can be observed with overexpression of p53β or the
knockdown of ∆133p53α isoforms. Indeed, in the brain tissue of patients with Alzheimer’s disease and
amyotrophic lateral sclerosis, p53βwas upregulated and ∆133p53α isoforms downregulated compared
to age-matched normal brain tissue [123]. More recently, in response to irradiation, ∆133p53α isoforms
were observed to have a protective role against radiation-induced brain injury (risk of reduced cognitive
and vocational ability), via inhibiting senescence and preventing astrocyte-derived neuroinflammation
in human astrocytes [123].
p53 isoforms can mediate a chronic pro-inflammatory state similar to disease states observed in
autoimmune inflammatory arthropathies and vasculitis. Serum analysis of mice expressing ∆122p53
isoforms revealed increased expression of inflammation-associated cytokines such as IFNγ, TNFα,
IL6, CCL2 and GM-CSF. When IL-6 was depleted in these mice, fewer tumours were observed and
mediators of the JAK-STAT signalling pathway were downregulated, supporting a role for p53 isoform
induced inflammation in carcinogenesis [31].
Bacterial and viral exposure is a recognized form of cell stress. Viral infections are especially
well-established deregulators of the p53 pathway (e.g., HPV, the Epstein Barr virus or influenza
virus). Helicobacter pylori can upregulate the expression of ∆133p53 isoforms in vivo via activation of
transcription factors cFOS/cJun ultimately deregulating p53α [123]. This reduced p53α mediated stress
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response signalling, allowing continued progression of helicobacter pylori-associated pathogenesis
and eventually tumorigenesis.
In Drosophila, p53 isoforms can mediate tissue regeneration by influencing apoptosis-induced
proliferation (AiP) which is a phenomenon characterized by the release of mitogens such as hedgehog
(Hh) and wingless following stress stimulus to promote the proliferation of adjacent cells to restore
organ integrity and function [22,124,125]. In mice, the splice Mp53Ψ isoform is upregulated in stem cells
in a tissue-specific manner following a damaging event. In liver tissue, CCL4-induced lesions regress
in size following expression of Mp53Ψ, supporting its role in tissue regeneration. In humans, however,
endogenous Mp53Ψ has only been characterized in the HOP62 cancer cell line which possesses a
mutation in the acceptor splice site of TP53 intron 6 [32]. This, therefore, associates TP53 splice site
mutations with oncogenic functions. Taken together, much of the evidence on p53 isoform role in
tissue regenerations is convincing albeit limited to animal models.
7. Detecting p53 Isoforms
RT-qPCR has been the most widely used and reliable technique to investigate p53 isoform
expression. Alternatively, the approach to detect p53 isoform expression at the transcriptome level
via analysis of RNA-sequence data from large cancer repositories such as The Cancer Genome Atlas
(TCGA) proves challenging with the available bioinformatic platforms (RSEM method) having poor
sensitivity for detecting low abundance splice variants [126]. The challenge with deriving conclusions
based on the level of p53 mRNA variants is that their expression levels do not always correlate with the
protein expression level of the corresponding isoforms [22]. Several antibodies have been developed to
investigate p53 isoform expression at the protein level using Western blotting, immunohistochemistry
(IHC) or immunofluorescence [22]. The use of IHC remains a common technique to investigate TP53
mutational status in routine pathology [127]. Therefore, given the significance of p53 isoforms in
multiple biological processes, it would be a logical endeavour to investigate p53 isoform expression
and their spatiotemporal distribution in normal, precancerous and cancer tissues by IHC. Several
groups have attempted to identify p53 isoforms with IHC with varying degrees of success [92,102,128].
Significant limitations experienced include the paucity of p53 isoform-specific antibodies and weak
signal intensity. The latter is an expected challenge in attempting to visualize p53 isoforms, including
p53α, via IHC as they are not as abundantly expressed as structural proteins such as actin, vimentin and
cytokeratin. Additionally, as p53α is notorious for extensive PTMs, one would expect p53 isoforms to
also be similarly modified, thus potentially affecting the target epitope of the isoform-specific antibodies.
Other methods to study isoform expression in situ include RNAscope in situ hybridisation which
has been employed to study ∆133p53β expression in formalin-fixed paraffin-embedded glioblastoma
tissue [102]. Targeted proteomics with liquid chromatography-tandem mass spectrometry (LC-MS/MS)
is emerging as a reliable method to quantify p53 isoform expression at the protein level. For example,
Jiang et al. combined molecularly imprinted polymers and LC-MS/MS to reliably quantify C-terminus
p53 isoform variants in several breast cancer cell lines [129].
8. Concluding Remarks
Based on the accumulated evidence, it is gradually becoming evident that the dysregulation
of p53 isoform balance is biologically relevant not only in the pathogenesis of cancer but also in
neurodegenerative, inflammatory, infection and progeria associated diseases. Investigating p53
isoforms offers a new vantage point to analyse and unravel the multiple biological functions of p53,
which have been elusive to therapeutic targeting in the last few decades. Numerous questions remain;
hence, a rigorous, concerted effort is essential to (1) develop more p53 isoform-specific antibodies with
appreciation of PTMs; (2) interrogate the mechanism underpinning the shift in isoform balance in
response to a particular cell context or stimulus; and (3) design clinical studies which investigate the
co-expression of p53 isoforms with outcomes. These are key steps towards deciphering the role of p53
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isoforms in both pathology and physiology and determine how clinicians can manipulate the isoforms’
activities to rationally trigger the appropriate tumour response on patient clinical outcomes.
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Abbreviations
IRES Internal ribosome entry site
TAD Transactivation domain
IDR Intrinsic disorder region
DBD DNA-binding domain
PTM Post-translational modifications
HGPS Hutchinson-Gilford Progeria Syndrome
SASP Senescence associated secretory phenotype
AIP Apoptosis-induced proliferation
Hh Hedgehog
IHC Immunohistochemistry
PRD Proline-rich domain
HD Hinge domain
LFS Li Fraumeni Syndrome
AML Acute myeloid leukaemia
PARP Poly-ADP ribose polymerase
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